InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | $82.0M+2.4% | $80.0M-3.8% | $83.2M+16.8% | $71.3M+16.6% | $61.1M |
| General and administrative | $21.2M+18.0% | $18.0M+12.5% | $16.0M+4.9% | $15.3M+14.8% | $13.3M |
| Total operating expenses | $103.2M+5.3% | $98.1M-1.2% | $99.2M-17.0% | $119.5M+30.4% | $91.7M |
| Loss from operations | -$103.2M-5.3% | -$98.1M+1.2% | -$99.2M+17.0% | -$119.5M-30.4% | -$91.7M |
| Interest income | $1.0M-69.3% | $3.4M+10.2% | $3.1M+195.4% | $1.0M+1477.3% | $66K |
| Change in fair value of the tranche rights | $0+100.0% | -$4.8M | $0 | — | — |
| Other income (expense), net | $5.0M+578.2% | -$1.0M-141.4% | $2.5M+229.4% | -$2.0M-45.6% | -$1.3M |
| Total other income (expense), net | $6.1M+346.7% | -$2.5M-143.8% | $5.6M+710.6% | -$919K+28.2% | -$1.3M |
| Net loss | -$97.2M+3.3% | -$100.5M-7.4% | -$93.6M+22.3% | -$120.4M-29.5% | -$92.9M |
| Net loss per share, basic (in usd per share) | -$620+38.0% | -$1K+52.6% | -$2K+44.2% | -$4K+3.8% | -$4K |
| Net loss per share, diluted (in usd per share) | -$620+38.0% | -$1K+52.6% | -$2K+44.2% | -$4K+3.8% | -$4K |
| Weighted-average common shares outstanding, basic (in shares) | $155.69B+55.4% | $100.17B+126.0% | $44.32B+39.3% | $31.82B+34.5% | $23.65B |
| Weighted-average common shares outstanding, diluted (in shares) | $155.69B+55.4% | $100.17B+126.0% | $44.32B+39.3% | $31.82B+34.5% | $23.65B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Immunic names Erik Lundgren as CEO; Daniel Vitt steps down